GENFIT to host a series of KOL Meetings in NASH
- Planned events will feature presentations from renowned Key Opinion Leaders specialized in the clinical management of NASH
- Meetings to kick off with a KOL lunch in Boston on March 30th followed by different cities in the US and EU, including events in New York, Amsterdam (EASL), and London
Lille (France), Cambridge (Massachusetts, United States), March 28, 2016 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, announced today that it will host a series of Key Opinion Leader (KOL) meetings focused on the NASH space for institutional investors and research analysts in Europe and the United States over the course of the coming months.
The meetings will feature presentations by renowned Key Opinion Leaders in the NASH space and intend to provide a global overview on this disease, and an opportunity to the financial community for in-depth interactions with NASH experts. The topics of the meetings will include clinical management of NASH patients, diagnostics for NASH and potential combination therapy approaches. Additionally, GENFIT management will provide an overview of the Company's pipeline, including biomarker development program in NASH.
Details of the first upcoming KOL meetings are as follows:
- Boston on March 30, 2017: NASH KOL Lunch with Dr. Manal F. Abdelmalek
Manal F Abdelmalek, MD, MPH is Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Duke University, with expertise in epidemiology, public health, clinical trial design, and clinical-translational research in NAFLD/NASH. She directs the Duke NAFLD Clinical Research Program. As one in the founding investigators in the field of NASH, she has 20 years experience in the successful implementation and conduct of clinical trials in NAFLD/NASH.
· New-York on April 4, 2017: NASH KOL Breakfast with Dr. Rohit Loomba
Dr. Rohit Loomba is Professor of Medicine (with tenure) in the Division of Gastroenterology, and Adjunct Professor in the Division of Epidemiology at University of California, San Diego. He is a leading expert in translational research and innovative clinical trial design in NAFLD (nonalcoholic fatty liver disease) and NASH. Dr. Loomba is the founding director of the UCSD NAFLD Translational Research Unit where his team is conducting cutting edge research in all aspects of NAFLD.
Attendance at the KOL events is intended for institutional investors and analysts.
About elafibranor:
Elafibranor is GENFIT's lead pipeline product. Elafibranor is an oral once-daily treatment, and a first-in-class drug acting via dual peroxisome proliferator-activated alpha/delta pathways developed to treat, in particular, nonalcoholic steatohepatitis (NASH). Elafibranor is believed to address multiple facets of NASH, including inflammation, insulin sensitivity, lipid/metabolic profile, and liver markers.
About NASH:
"NASH", or nonalcoholic steatohepatitis, is a liver disease characterized by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes. The disease is associated with long term risk of progression to cirrhosis, a state where liver function is diminished, leading to liver insufficiency, and also progression to liver cancer.
About GENFIT:
GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 120 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com
Forward Looking Statement / Disclaimer:
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 7 "Main Risks and Uncertainties" of the Company's Half Year 2016 Business and Financial Report, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF (www.amf-france.org). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.
CONTACT
GENFIT | Jean-François Mouney - Chairman & CEO | Ph. +333 2016 4000
MILESTONES - Press Relations | Bruno Arabian | Ph. +331 8362 3484 / +336 8788 4726 - barabian@milestones.fr
